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Does Not Eliminate the Need for Total-Body Irradiation
in Nonmyeloablative Conditioning Regimens for
Hematopoietic Cell Transplantation
Marco Mielcarek, Beverly Torok-Storb, Rainer StorbIn the dog leukocyte antigen (DLA)-identical hematopoietic cell transplantation (HCT)model, stable marrow
engraftment can be achieved with total-body irradiation (TBI) of 200 cGy when used in combination with
postgrafting immunosuppression. The TBI dose can be reduced to 100 cGy without compromising engraft-
ment rates if granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells
(G-PBMC) are infused with the marrow. T cell-depleting the G-PBMC product abrogates this effect. These
results were interpreted to suggest that the additional T cells provided with G-PBMC facilitated engraftment
by overcoming host resistance. We therefore hypothesized that the TBI dose may be further reduced to 50
cGy by augmenting immunosupression either by (1) tolerizing or killing recipient T cells, or (2) enhancing the
graft-versus-host (GVH) activity of donor T cells. To test the first hypothesis, recipient T cells were activated
before HCT by repetitive donor-specific PBMC infusions followed by administration of methotrexate (MTX)
(n 5 5), CTLA4-Ig (n 5 4), denileukin diftitox (Ontak; n 5 4), CTLA4-Ig 1 MTX (n 5 8), or 5c8 antibody
(anti-CD154)1MTX (n5 3). To test the second hypothesis, recipient dendritic cells were expanded in vivo
by infusion of Flt3 ligand given either pre-HCT (n 5 4) or pre- and post-HCT (n 5 5) to augment GVH re-
actions. Although all dogs showed initial allogeneic engraftment, sustained engraftment was seen in only 6 of
42 dogs (14% of all dogs treated in 9 experimental groups). Hence, unless more innovative pharmacotherapy
can be developed that more forcefully shifts the immunologic balance in favor of the donor, noncytotoxic
immunosuppressive drug therapy as the sole component of HCT preparative regimens may not suffice to
ensure sustained engraftment.
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chimerism, Tolerance, ImmunosuppressionINTRODUCTION
Nonmyeloablative conditioning for allogeneic he-
matopoietic cell transplantation (HCT) is associated
with lower regimen-related toxicities than myeloabla-
tive conditioning. This has made HCT a treatment
option for a broader range of diseases, a well as older
or medically infirm patients [1]. The clinical nonmye-
loablative preparative regimen used at the FredredHutchinsonCancer Research Center and theUniver-
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been developed in the preclinical canine model and
relies on low-dose total-body irradiation (TBI; 200
cGy), and postgrafting immunosuppression with cy-
closporine (CSP) and mycofenolate mofetil (MMF)
[2]. Both TBI and pharmacological immunosuppres-
sion are required to prevent recipient T cell-mediated
graft rejection. However, even 200 cGy TBI may
increase the risk of late toxicity such as secondary
malignancies [3,4], complications that need to be
avoided in patients with nonmalignant diseases who
may otherwise benefit from allogeneic HCT [5,6].
To address this issue, we proposed to further re-
duce the TBI dose by replacing its immunosuppressive
function with additional immunomodulation strate-
gies. In theory, this may be achieved by inducing
recipient-antidonor tolerance before transplant, inten-
sifying the immunosuppressive treatment after
transplant, or enhancing engraftment-facilitating graft-
versus-host (GVH) activities. In the current study,1255
1256 Biol Blood Marrow Transplant 17:1255-1260, 2011M. Mielcarek et al.we asked whether any of the outlined strategies would
permit TBI dose reduction to 50 cGy without compro-
mising the rate of sustained engraftment. We had pre-
viously shown that sustained engraftment could be
achieved in the majority of recipients prepared with
100 cGy TBI if they were given a combination of dog
leukocyte antigen (DLA)-identical bone marrow
plus granulocyte colony-stimulating factor (G-CSF)–
mobilized peripheral blood mononuclear cells
(G-PBMC) followedby 5weeks ofCSP after transplant
[7]. We found in the current study, however, that with
50 cGy TBI, immunosuppressive and/or tolerance-
inducing strategies employed led to overall sustained
engraftment in only 14% of recipients treated in 9 dif-
ferent experimental groups. These findings illustrate
the difficulty to uniformly achieve sustained engraft-
ment with pharmacological immunosuppression given
in combination with TBI doses at or below 100 cGy.METHODS
Dogs
The Institutional AnimalCare andUseCommittee
of the FHCRC approved this study. Hematopoietic
cell grafts were carried out using beagle or miniature
mongrel-beagle crossbreeds, and standard care was
provided as described previously [7-9]. Recipients
(n 5 42) were 6.8 to 27.5 (median, 8.6) months old
and weighed 7.1 to 16.8 (median, 10.0) kg. The
donors (n 5 41) were 6.8 to 24.3 (median, 8.6)
months old and weighed 7.0 to 19.0 (median, 12.7)
kg. One dog served as the donor for 2 recipients.
Forty-two donor/recipient littermate pairs were in-
cluded in 9 HCT protocols that substituted minimally
toxic immunomodulation for TBI. The pairs were
DLA-identical on the basis of matching for highly
polymorphicDLA-associated class I and class IImicro-
satellite markers [10], which was confirmed by DLA-
DRB1 allele sequencing [11].
HCT
The following treatment applied to all experimen-
tal groups. The day of hematopoietic stem cell grafting
was designated as day 0. Thirty days before HCT,
marrow for transplantation was aspirated from the do-
nors under general anesthesia through needles inserted
into the humeri and cryopreserved. On days 25 to 0,
donors were treated by subcutaneous injection with re-
combinant canine G-CSF (gift from Amgen, Inc.,
Thousand Oaks, CA) at 10 mg/kg per day. Leukapher-
eses were performed on day 0 via an intravenous
catheter and a continuous flow blood separator
(CobeSPECTRA, Cobe Laboratories, Lakewood,
CO) [12]. On day 0, recipients were given a single
dose of 50-cGy TBI delivered at 7 cGy/min from
a high-energy linear accelerator (Varian CLINAC 4,Palo Alto, CA) followed by infusion of bone marrow
and G-PBMC. Except for experimental group 1,
which was treated with CSP alone, all experimental
groups received a combination of CSP (15 mg/kg
twice daily orally on days 1-35) and MMF (10 mg/kg
twice daily subcutaneously on days 0-27) for immuno-
suppression after transplantation. Blood CSP levels
were measured on days 7 and 21 and targeted at 400
to 800 ng/mL. Nine different immunomodulatory
regimens were studied, and recipient treatments (n 5
42) (Table 1) are summarized below:
 Group 1 (n5 5): Postgrafting CSP alone as outlined
above. No further immunomodulation.
 Group 2 (n 5 4): Postgrafting CSP and MMF as
outlined above. No further immunomodulation.
 Group 3 (n 5 5): Donor PBMC (5  106/kg) infu-
sions on days 25 and 23. Methotrexate (MTX)
(0.4 mg/kg intravenously [i.v.]) was given on days
24 and 22 [13]. Postgrafting CSP and MMF.
 Group 4 (n5 4): Donor PBMC (2 106/kg/day) in-
fusions on days27 until21. rhCTLA4-Ig (4.0 mg/
kg/day i.v.; provided by RepliGen, Waltham, MA)
was given on days 27 until 21. Postgrafting CSP
and MMF.
 Group 5 (n5 4): Donor PBMC (2 106/kg/day) in-
fusions on days 28 until 22. Denileukin diftitox
(Ontak; 18.0 mg/kg/day i.v.; Eisai Pharmaceuticals,
Teaneck, NJ) was given on days 27 until 21. Post-
grafting CSP and MMF.
 Group 6 (n5 8): Donor PBMC (2 106/kg/day) in-
fusions on days27 until22. rhCTLA4-Ig (4.0 mg/
kg/day i.v.) was given on days 27 until 22. MTX
(0.4 mg/kg i.v.) was given on days 26, 24, and
22. Postgrafting CSP and MMF.
 Group 7 (n 5 3): Ketorolac (0.5 mg/kg i.v.) was
given on days29 and28 as thrombembolic prophy-
laxis before i.v. use of the 5c8 humanized monoclo-
nal antibody (mAb) directed against CD154 (CD40
ligand) [9]. The 5c8 mAb (0.5 mg/kg i.v.) was then
given on day 28. Donor PBMC (2  106/kg/day
i.v.) were given on days 27 until 23. MTX (0.4
mg/kg i.v.) was given on days26,24, and22. Post-
grafting CSP and MMF.
 Group 8 (n 5 5): Recombinant human fetal Liver
Tyrosine Kinase-3 (rhFlt-3) ligand (FL; 100 mg/
kg/day subcutaneously; provided by Amgen, Seattle,
WA) was given on days 210 until 0. Postgrafting
CSP and MMF [14].
 Group 9 (n 5 4): FL was given on days 210 until
110. Postgrafting CSP and MMF.
All dogs were given standard postgrafting care that
included systemic enrofloxacin (Baytril [Shawnee Mis-
sion, KS, USA]), from day 25 until hematopoietic re-
covery from radiation nadirs occurred. The clinical
status of the dogs was assessed twice daily. Upon com-
pletion of the study, dogs were euthanized, adopted, or
Table 1. Duration and Level of Mixed Donor Chimerism Among Dogs (n5 42) Prepared with 50-cGy Total-Body Irradiation (TBI;
Dose Rate, 7 cGy/min) and Different Immunomodulatory Regimens before DLA-Identical Marrow/G-CSF-Mobilized PBMC
Transplantation
Experiment
Number
Immunosuppression
N
Mean TNC Dose
per kg Recipient
Weight (108/kg)
Peak Chimerism in Granulocyte
Fraction within First 12 Weeks
after HCT (%)
Stable Mixed
Chimerism > 26 Weeks
after HCT, n (%)
Before HCT
After HCT BM G-PBMC
Duration of Mixed Chimerism
(Weeks)Drug
Donor
PBMC
1 — No CSP 5 3.9 8.4 35, 25, 20, 15, 15 1 (20)
10, 9, >36, 11, 9
2 — No CSP/MMF 4 4.6 6.9 40, 30, 20, 10 1 (25)
14, 14,>36, 7
3 MTX Yes CSP/MMF 5 4.5 6.8 75, 55, 55,10,10 1 (20)
>36,12, 6, 9, 8
4 CTLA4-Ig Yes CSP/MMF 4 5.2 7.3 35, 28, 22, 13 1 (25)
>36, 9, 8, 12
5 Ontak Yes CSP/MMF 4 4.7 7.9 52, 49, 16, 9 0 (0)
12, 11, 12, 12
6 CTLA4-Ig/MTX Yes CSP/MMF 8 4.5 8.2 100, 89, 45, 34, 30, 23, 20, 15 1 (12)
14, 12, >36, 8, 8, 9, 10, 9
7 5c8/MTX Yes CSP/MMF 3 4.7 4.6 25, 21, 13 0 (0)
11, 9, 19
8 FL No CSP/MMF/FL 5 5.2 7.5 14, 9, 7, 7, 5 0 (0)
10, 9, 8, 8, 7
9 FL No CSP/MMF 4 5.8 8.5 15, 15, 10, 5 1 (25)
>36, 5, 15, 10
Total 42 6 (14)
MTX indicates methotrexate; FL, rhFlt3 ligand; CTLA4-Ig, Cytotoxic T-Lymphocyte Antigen 4; Ontak, denileukin diftitox; 5c8, humanized monoclonal
antibody directed against CD154 (CD40 ligand); HCT, hematopoietic cell transplantation; Donor PBMC, infusion of donor peripheral blood mononu-
clear cells; TNC, total nucleated cells; BM, bonemarrow; G-PBMC, G-CSF–mobilized peripheral bloodmononuclear cells. The bolded percentage values
in the category ‘‘Peak granulocyte chimerism within 12 weeks after HCT’’ indicate recipient dogs with sustained mixed donor/host chimerism.
The different immunomodulatory regimens (Experiments 1-9) are detailed in the Methods section. Except for recipients in experimental group 1 that
were treated with cyclosporine (CSP) alone, recipients in all other groups received a combination of CSP (15 mg/kg twice daily orally on days 1-35) and
mycophenolate mofetil (MMF; 10 mg/kg twice daily subcutaneously on days 0-27) for immunosuppression after transplant.
Biol Blood Marrow Transplant 17:1255-1260, 2011 1257Pharmacologic Immunosuppression and HCTtransferred to other studies. When euthanized, they
underwent complete necropsies with histological ex-
aminations of tissue samples.
Assessment of Chimerism
The presence of donor cells among PBMC and
granulocytes after HCT was assessed by fluorescent
variable number tandem repeat polymerase chain
reaction (PCR) assays using an ABI Prism 310 Genetic
Analyzer and Gene Scan 3.1 software (Applied BioSys-
tems, Foster City, CA) as described [15,16]. The
endpoint of the study was stable mixed donor/host
hematopoietic chimerism beyond 26 weeks after
HCT. This time point was chosen because
historically, no graft rejections were seen after week 26.RESULTS AND DISCUSSION
Our previous studies in the DLA-identical HCT
model demonstrated that the addition of G‑PBMC
to DLA-identical marrow grafts allowed for the
reduction of TBI dose from 200 cGy to 100 cGy and
required only CSP for postgrafting immunosuppres-
sion to achieve stable mixed chimerism in 5 of 8 dogstransplanted [7]. In this model, graft rejection, if it
occurs, is typically completed within the first 26 weeks
after HCT. The engraftment-facilitating effect associ-
ated with G-PBMC in this model was mediated by the
relatively large number of additional T cells because
only 1 of 7 recipients had sustained mixed donor
chimerism when G-PBMC products were T cell
depleted. Based on these findings, we hypothesized
that the TBI dose sufficient for sustained engraftment
in the majority of recipients in this model (100 cGy)
could be further reduced by (1) tolerizing or killing
rejection-mediating host T cells or (2) enhancing
engraftment-facilitating GVH reactions.
In preparation for testing these 2 hypotheses, we
first showed that a TBI dose reduction from 100 cGy
to 50 cGy was not sufficient to ensure sustained mixed
chimerism in the majority of recipients (Experiment 1:
rate of sustained engraftment, 1 of 5 dogs, 20%)
(Table 1). We then showed that intensifying the post-
tranplant immunosuppressive regimen by adding 4
weeks ofMMF did not significantly improve this result
(experiment 2: rate of sustained engraftment, 1 of 4
dogs, 25%) (Figure 1).
After having established 100 cGy TBI as a critical
threshold dose for sustained engraftment in this
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Figure 1. Mixed hematopoietic chimerism in dogs (n 5 4) prepared
with 50-cGy total-body irradiation (TBI) and given DLA-identical
marrow and G-PBMC grafts, followed by cyclosporine (CSP) and myco-
fenolate mofetil (MMF) for immunosuppression after transplant. CSP,
15 mg/kg twice daily orally on days 1 to 35; MMF, 10 mg/kg twice daily
subcutaneously on days 0 to 27. Donor chimerism was assessed as de-
scribed in Methods in the granulocyte fraction (upper panel) and mono-
nuclear cell fraction (lower panel). Identification numbers of recipient
dogs are listed in the box.
Figure 2. Mixed hematopoietic chimerism in dogs (n 5 5) prepared
with donor PBMC infusions and intravenous methotrexate (MTX) be-
fore 50-cGy total-body irradiation (TBI) and DLA-identical marrow/
G-PBMC transplantation, followed by cyclosporine (CSP) and mycofe-
nolate mofetil (MMF) immunosuppression after transplant. Donor
PBMC (5  106/kg) infusions were given on days 25 and 23. MTX
(0.4 mg/kg i.v.) was given on days24 and22. CSP, 15 mg/kg twice daily
orally on days 1 to 35; MMF, 10 mg/kg twice daily subcutaneously on days
0 to 27. Donor chimerism was assessed as described in Methods in
the granulocyte fraction (upper panel) and mononuclear cell fraction
(lower panel). Identification numbers of recipient dogs are listed in
the box.
1258 Biol Blood Marrow Transplant 17:1255-1260, 2011M. Mielcarek et al.model, subsequent experiments were aimed at over-
coming the engraftment barrier encountered after
50-cGy TBI by tolerizing or killing rejection-
mediating host T cells before transplant. For this
purpose, host T cells were activated by repetitive
donor-specific PBMC infusions that were followed by
administration of methotrexate (MTX), CTLA4-Ig,
or Ontak (Experiments 3-5). Using these 3 ap-
proaches, rates of sustained engraftment ranged
between 0% and 25% and, hence, were not signifi-
cantly different from the 25% observed with controls
given no immunomodulatory treatment before trans-
plant (exemplified in Figure 2). Even though peak chi-
merism levels within the first 12 weeks after HCT
appeared higher in recipients given pretransplant
donor-specific PBMC andMTX compared to controls
(median, 55% versus 25%), this difference was not sta-
tistically significant (P5 .56) (Figure 2). Furthermore,
combined modalities of pretransplant conditioning of
recipients with donor-specific PBMC followed by
CTLA4-Ig and MTX, or 5c8 antibody and MTX
proved as ineffective as the singular strategies tested
in Experiments 3-5.
We had previously shown that the TBI dose re-
quired for sustained engraftment after DLA-identical
marrow transplantation (without G-PBMC coinfu-
sion) could be reduced from 200 cGy to 100 cGy ifrecipients were tolerized against donor marrow with
pretransplant donor PBMC/CTLA4-Ig infusions
[17]. In addition, donor-specific PBMC infusions and
CD154 blockade with the 5c8-antibody not only de-
layed marrow graft rejection but also improved rates
of sustained engraftment [9]. Even though these con-
cepts were directly translated to the current model,
they proved unsuccessful. The difficulty to attain sus-
tained engraftment with 50-cGy TBI in this model is
likely related to the fact that the chosen immuno-
suppressive strategies did not sufficiently compromise
host T cell function to shift the immunologic balance
toward the donor. We have shown previously that
TBIdoses of 200 cGy cause substantiallymore effective
T cell depletion and suppression of T cell function
than TBI doses of 100 cGy, illustrating the steep
dose-response relationship at low doses of ionizing
radiation [18].
An alternative explanation for the difficulty to at-
tain sustained engraftment with 50-cGy TBI may be
related to the fact that, in preparative regimens that
primarily rely on low-dose TBI for host immunosup-
pression, ionizing radiation may serve the additional
purpose of providing a competitive advantage to donor
hematopoietic stem cells [19]. In fact, competitive
Biol Blood Marrow Transplant 17:1255-1260, 2011 1259Pharmacologic Immunosuppression and HCTrepopulation studies using irradiated versus nonirradi-
ated human CD34 cells in NOD/SCID mice showed
that 100 cGy reduced engraftment by 24% [19].
Therefore, although the pharmacological pretrans-
plant strategies tested might tolerize or kill host T
cells, and thereby have immunosuppressive activity,
one could argue that they might not sufficiently com-
promise the recipient’s stem cell compartment. How-
ever, the validity of the latter hypothesis is challenged
by the observation that sustained engraftment has been
achieved in dogs given marrow space-sparing lymph
node irradiation (450 cGy) before and pharmacologi-
cal immunosuppression with CSP and MMF after
DLA-identical marrow transplantation [8]. Further-
more, clinical observations suggest that long-term sta-
ble donor/host chimerism can be achieved in patients
with primary immunodeficiency disorders without us-
ing a preparative regimen before HCT provided phar-
macological immunosuppression is given after HCT
[20,21].
Our second approach aimed at achieving sustained
engraftment after 50 cGy involved enhancing
engraftment-facilitating GVH reactions. For this pur-
pose, recipients were treated with FL to expand the
dendritic cell (DC) compartment and make T cells
more ‘‘visible’’ to engraftment-facilitating GVH-reac-
tions (Experiments 8 and 9). This approach has been
shown to facilitate engraftment in the canine HCT
model that uses DLA-identical bone marrow and an
otherwise suboptimal TBI dose of 450 cGy without
postgrafting immunosuppression [22]. We had shown
previously that 10 days of FL treatment of dogs re-
sulted in a doubling of the total white blood cell count,
which was largely attributable to an approximately 10-
fold increase in the number of CD141monocytes [14].
Moreover, FL treatment led to the emergence of a dis-
tinct CD11c1/HLA-DR1/CD142 cell population,
a surface marker profile consistent with that of myeloid
DC in humans. As few as 5  103 irradiated CD11c1/
HLA-DR1/CD142/DM52 cells elicited strong pro-
liferative T cell responses in unidirectional, allogeneic
MLC [14]. The identification of these highly potent
antigen-presenting cells in the peripheral blood of
dogs, which may represent the equivalent of myeloid
DC in humans, prompted us to investigate whether ex-
pansion of these cells would enhance GVH reactions
leading to sustained engraftment.
Our results showed that 10-day FL treatment of re-
cipients beforeHCT (FL1/–), or 10 days beforeHCT
and 10 days after HCT (FL 1/1), did not have
engraftment-facilitating effects in the 50-cGy TBI
model. Indeed, levels of peak granulocyte chimerism
in the FL1/1 group (Experiment 8) were significantly
lower than those in controls (median, 7% versus 25%,
P5 .03) (Table 1), suggesting a counterproductive ef-
fect of FL administration afterHCT. Only 1 of 9 dogs
conditioned with FL had sustained engraftment. Thisdog did not experience clinically apparent graft-
versus-host disease (GVHD), which could have been
a concern after recipient-DC expansion [23].
In summary, only 5 of 37 (14%) recipients had sus-
tained mixed chimerism when conditioned with
50-cGy TBI and given combined DLA-identical mar-
row/G-PBMC grafts followed by immunosuppression
with CSP and MMF after transplant. None of the
tested immunomodulatory regimens improved rates
of engraftment or levels of donor chimerism above
those of controls. Even though we did not provide
direct evidence in the present study that the chosen
immunomodulatory approaches inhibited host-
antidonor activity or enhanced donor-antihost reac-
tions, there is ample evidence from previously
conducted and published studies that this is indeed the
case [9,17,24]. The fact that substituting minimally
toxic pharmacological immunomodulation for TBI
did not overcome the engraftment barrier in this
model is evidence for the potent immunosuppressive
effects of even low doses of ionizing radiation [18].
Thus, in HCT preparative regimens without any or
with very low doses of TBI, conventional immunosup-
pressive drug therapy may not suffice to achieve sus-
tained engraftment. In order to more forcefully shift
the immunologic balance in favor of the incoming do-
nor cellswithout having to rely onTBI,more innovative
pharmacotherapy needs to be developed.ACKNOWLEDGMENTS
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